Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17258080 | 0.89 | IDO1 (1.00) | IDO1CYP2C19ABCG2LMNA | |
| Pf-06840003 SCHEMBL29362517 | 0.83 | IDO1 (1.00) | IDO1CYP2C19ABCG2LMNA | |
| SCHEMBL5879150 | 0.83 | IDO1 (0.71) | IDO1CYP2C19ABCG2LMNA | |
| SCHEMBL1445100 | 0.83 | IDO1 (1.00) | IDO1CYP2C19ABCG2LMNA | |
| Pf-06840003 SCHEMBL17258084 | 0.83 | IDO1 (1.00) | IDO1CYP2C19ABCG2LMNA | |
| Pf-06840003 SCHEMBL5463464 | 0.83 | IDO1 (1.00) | IDO1CYP2C19ABCG2LMNA | |
| SCHEMBL5879236 | 0.83 | IDO1 (1.00) | IDO1CYP2C19ABCG2LMNA | |
| Pf-06840003 SCHEMBL17258024 | 0.83 | IDO1 (1.00) | IDO1CYP2C19ABCG2LMNA | |
| SCHEMBL17258134 | 0.83 | IDO1 (1.00) | IDO1CYP2C19ABCG2LMNA | |
| SCHEMBL17258025 | 0.83 | IDO1 (1.00) | IDO1CYP2C19ABCG2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10398679-B2 | Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors | ITEOS THERAPEUTICS (BE) | 2019-09-03 | — | — | US | claimed |
| US-20180214415-A1 | TREATMENT METHOD UTILIZING PYRROLIDINE-2, 5-DIONE DERIVATIVES AS IDO1 INHIBITORS | ITEOS THERAPEUTICS (BE) | 2018-08-02 | — | — | US | claimed |
| US-9949951-B2 | Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors | ITEOS THERAPEUTICS (BE) | 2018-04-24 | — | — | US | claimed |
| EP-3148531-A1 | PYRROLIDINE-2,5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS | iTeos Therapeutics (BE) | 2017-04-05 | — | — | EP | claimed |
| US-9603836-B2 | Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors | ITEOS THERAPEUTICS (BE) | 2017-03-28 | — | — | US | claimed |
| US-20170035731-A1 | PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS | ITEOS THERAPEUTICS (BE) | 2017-02-09 | — | — | US | claimed |
| US-20150329525-A1 | PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS | ITEOS THERAPEUTICS (BE) | 2015-11-19 | — | — | US | claimed |
| WO-2015173764-A1 | PYRROLIDINE-2,5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS | ITEOS THERAPEUTICS (BE) | 2015-11-19 | — | — | WO | claimed |
| US-20220323558-A1 | CANCER VACCINES | PFIZER INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-11058753-B2 | Cancer vaccines | PFIZER INC. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3733201-A1 | CANCER VACCINES | Pfizer Inc (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3405212-B1 | CANCER VACCINES | PFIZER (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3651792-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING CEA MUC1 AND TERT | Pfizer Inc (US) | 2020-05-20 | — | — | EP | disclosed |
| CN-111065408-A | Immunogenic compositions | 辉瑞公司 | 2020-04-24 | — | — | CN | disclosed |
| US-20150329525-A1 | PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS | ITEOS THERAPEUTICS (BE) | 2015-11-19 | — | — | US | disclosed |
| US-20150329525-A1 | PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS | ITEOS THERAPEUTICS (BE) | 2015-11-19 | — | — | US | disclosed |
| US-7151108-B2 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATORIES SERVIER (FR) | 2006-12-19 | — | — | US | disclosed |
| EP-1411057-B1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATOIRES SERVIER (FR) | 2004-04-22 | — | — | US | disclosed |
| EP-1411057-A1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2004-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035731-A1 | PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS | IDO1, IDO2, ARG1 | IDO1 1/4885CYP2C19 379/4885ABCG2 2352/4885 |
| US-20150329525-A1 | PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS | IDO1, IDO2, ARG1 | IDO1 1/4885CYP2C19 238/4885ABCG2 2342/4885 |
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | XDH, TOP2A, TOP1 | IDO1 436/4885CYP2C19 1665/4885ABCG2 1462/4885 |
| US-20180214415-A1 | TREATMENT METHOD UTILIZING PYRROLIDINE-2, 5-DIONE DERIVATIVES AS IDO1 INHIBITORS | IDO1, IDO2, NAT1 | IDO1 1/4885CYP2C19 469/4885ABCG2 3270/4885 |
| US-10398679-B2 | Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors | IDO1, IDO2, NAT1 | IDO1 1/4885CYP2C19 469/4885ABCG2 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.